Safe Pain Medications During Pregnancy

Understanding Medication Safety in Pregnancy

No medication is entirely without risk during pregnancy, but some have well-established safety profiles supported by decades of clinical data and population studies. The decision to use any medication must weigh the potential risks to the fetus against the consequences of untreated maternal pain, which itself can adversely affect pregnancy outcomes through increased cortisol, poor nutrition, sleep deprivation, and depression.

In 2015, the FDA replaced the pregnancy letter categories (A, B, C, D, X) with the Pregnancy and Lactation Labeling Rule (PLLR), which provides more detailed narrative descriptions of risks. This guide reflects current evidence as of 2024.

First-Line: Acetaminophen (Paracetamol)

Acetaminophen remains the most widely recommended analgesic during pregnancy. It has been used for decades with a generally favorable safety profile, though recent research has prompted some reconsideration of unrestricted use.

Safety Evidence

• A 2021 consensus statement in Nature Reviews Endocrinology signed by 91 scientists raised concerns about potential endocrine-disrupting effects with prolonged use, but acknowledged that short-term use remains appropriate
• The European Medicines Agency Pharmacovigilance Risk Assessment Committee (2022) concluded the evidence does not support changing current guidance but recommends the lowest effective dose for the shortest duration
• ACOG (American College of Obstetricians and Gynecologists) continues to recognize acetaminophen as the preferred first-line analgesic in pregnancy

Dosing Guidelines

Maximum 2g per day (lower than the standard 4g adult maximum). Avoid sustained daily use exceeding 3–5 days without medical consultation. Hepatotoxicity risk is increased in pregnancy due to altered metabolism.

NSAIDs: Limited Use with Restrictions

Non-steroidal anti-inflammatory drugs (ibuprofen, naproxen) have trimester-specific safety profiles:

• First trimester: Some studies suggest a small increased risk of miscarriage. Use only when benefits clearly outweigh risks
• Second trimester (up to 20 weeks): Short-term use may be considered on a case-by-case basis
• After 20 weeks: Contraindicated. FDA warning (2020) highlighted risks of fetal renal dysfunction leading to oligohydramnios and premature closure of the ductus arteriosus

Aspirin at low dose (75–150 mg daily) is actually recommended in certain situations, such as preeclampsia prevention in high-risk women, and is not subject to the same restrictions as full-dose NSAIDs.

Topical Analgesics

Topical medications offer the advantage of reduced systemic absorption:

• Topical lidocaine (patches, creams): Minimal systemic absorption makes this a reasonable option for localized pain. Pregnancy category B equivalent
• Capsaicin cream: Limited data but minimal systemic absorption. May be used for localized muscle or joint pain
• Topical menthol: Generally considered safe for short-term use in small areas
• Topical diclofenac: Same trimester restrictions as oral NSAIDs apply due to potential systemic absorption, particularly with large application areas

Opioid Medications: Use with Caution

When non-opioid treatments are inadequate, certain opioids may be prescribed under close medical supervision:

• Codeine: Long track record but associated with neonatal withdrawal at sustained higher doses. CYP2D6 ultra-rapid metabolizers may produce toxic morphine levels
• Oxycodone/Hydrocodone: May be used short-term for severe acute pain. Neonatal Abstinence Syndrome (NAS) risk with prolonged use, occurring in 30–80% of exposed neonates
• Tramadol: Generally avoided due to serotonergic effects and limited safety data. Associated with neonatal seizures in some reports
• Buprenorphine: Preferred over methadone for opioid use disorder in pregnancy due to lower NAS severity (MOTHER trial, NEJM, 2010)

All opioid use in pregnancy should include a neonatology consultation to prepare for potential neonatal monitoring.

Adjuvant Pain Medications

Antidepressants for Pain

• SSRIs (sertraline, fluoxetine): Relatively well-studied in pregnancy. Sertraline has the most reassuring data for use in pregnancy. May help with pain and co-existing depression
• SNRIs (duloxetine, venlafaxine): Less data than SSRIs but may be continued if already effective pre-pregnancy. Risk of neonatal adaptation syndrome in third trimester
• TCAs (amitriptyline, nortriptyline): Long history of use with generally reassuring data. Nortriptyline may be preferred due to fewer anticholinergic effects

Anticonvulsants for Neuropathic Pain

• Gabapentin: Limited human data but animal studies suggest potential risks. Should be continued only if no suitable alternative exists. Neonatal withdrawal reported
• Pregabalin: Registry data suggest possible increased risk of major birth defects. Generally avoided in pregnancy
• Carbamazepine: Known teratogen (neural tube defects 0.5–1%). Folic acid supplementation (4–5 mg/day) is essential if continued

Muscle Relaxants

Most muscle relaxants have limited safety data in pregnancy:

• Cyclobenzaprine: Limited data; generally avoided but no clear teratogenic signal
• Magnesium supplementation: Safe and may help with muscle cramps and tension. Therapeutic levels are well-established in obstetric practice
• Baclofen: Limited human data; animal studies show some risks. Generally avoided unless essential

Medications to Avoid

References

1. ACOG Committee Opinion No. 711. Opioid use and opioid use disorder in pregnancy. Obstet Gynecol. 2017;130(2):e81–e94.
2. Bauer AZ, et al. Paracetamol use during pregnancy: a call for precautionary action. Nat Rev Endocrinol. 2021;17(12):757–766.
3. Jones HE, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010;363(24):2320–2331.
4. FDA Drug Safety Communication: NSAIDs in pregnancy. October 2020.
5. Ennis ZN, Bhatt DK, et al. The pharmacokinetics of paracetamol in pregnancy. Basic Clin Pharmacol Toxicol. 2023;132(5):382–393.
6. Bromley RL, et al. Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. Cochrane Database Syst Rev. 2014;(10):CD010236.